It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...
The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...
Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.
Investor's Business Daily on MSN1d
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?In the meantime, its Covid vaccine has yet to hit a bottom and its RSV vaccine is coming from behind in competition with ...
We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...
3don MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback